Tag: the war on (some) drugs

War Powers, Anyone?

When our country’s Founders were creating the Constitution, they had just won a war against King George III of England. They deliberately and unambiguously invested the power to wage war in the Congress, judging it to be more reticent about entering war than a head of state, who would see a war as an opportunity to increase his power.

Fast forward to today. America is embroiled in foreign wars that consume, with growing unease, our attention and resources. Yet the Senate on Thursday sunk legislation that would have required the White House to get congressional approval before attacking Venezuela. We should rely on the carefully designed constitutional structure our Founding Fathers provided to avoid further disasters and use those tools to extricate us from existing ones. 

During the 2024 election campaign, we were all told the wars were a waste and would be ended swiftly if Donald Trump won. It looks like we were fooled again.

Ukraine was supposed to be settled quickly. However, after the 10 months since President Trump’s inauguration, the current debate is whether to provide nuclear-capable Tomahawk missiles to reach deep into Russia, which has the largest nuclear arsenal in the world. Doesn’t our governing elite think shooting nuclear-capable missiles into Russia could be risky?

Recently, and with fanfare, the Palestinians released their hostages to the Israelis, but Israel’s military, using U.S. supplied and funded weapons, has repeatedly and dramatically violated the ceasefire. It looks like all the lofty rhetoric about peace deals was just hot air.

In less than a year in office, the Trump administration has directly engaged in the bombings or has supported the bombings of Gaza, Yemen, Iran, Syria, Lebanon, Somalia, and possibly Qatar. It has also been financing political turbulence in countries across Asia, the Western Hemisphere, and who knows how many in Africa. Alarmingly, Trump recently has started arguing for military intervention in Nigeria.

Over the past two months, the Trump administration has been illegally assassinating, without any due process, “suspected narco-terrorists” off the coasts of Latin America. The Washington elites are circulating stories sotto voce among themselves that there are Hezbollah terrorists in the Venezuelan jungles. Now, we are supposed to be really threatened. It won’t be long before they will be whispering about Hamas fighters training in Cuba to attack Key West, or even Miami!

These fairy tales are the latest additions to the long list of old discredited war propaganda gems such as: the sinking of the USS Maine in Havana Harbor, the German soldiers bayoneting and decapitating babies during World War I in France, the domino theory, the faked attack in the Gulf of Tonkin in Vietnam, Iraqi soldiers ripping babies out of incubators in Kuwait, Iraqi weapons of mass destruction, poison gas attacks in Syria, the fake Libyan mass rape claims, or of course the completely debunked claim of the many beheaded babies in Israel.

Keep reading

Carrier USS Ford Holding Off Of North Africa As Trump Reportedly Won’t Strike Venezuela

wo days after passing through the Strait of Gibraltar en route to the Caribbean, the aircraft carrier USS Gerald R. Ford has not moved significantly from a position just west of Morocco in North Africa, the Navy confirmed to us Thursday. The flattop and elements of its strike group were ordered by President Donald Trump to join the ongoing enhanced counter-narcotics mission in the region, but it is unclear if plans have changed.

The relatively static position of the Ford and at least two of its escorts comes as reports are emerging that the Trump administration has decided, for now, not to carry out land strikes against Venezuela. It is unknown at the moment if there is a correlation, and the possibility remains that the carrier could still soon sail westward. We have reached out to the White House for clarification.

The Trump administration on Wednesday told Congress it is holding off for now on strikes inside Venezuela out of concern over the legal authority to do so, CNN reported on Thursday. The briefing was conducted by Secretary of State Marco Rubio, Defense Secretary Pete Hegseth and an official from the White House’s Office of Legal Counsel, the network reported, citing sources familiar with the events.

Lawmakers were told that the authority given to suspected drug boats did not apply to land strikes, the network noted. So far, nearly 70 people have been killed in at least 16 publicly known attacks on vessels allegedly smuggling drugs in the Caribbean and Pacific. The most recent acknowledged strike took place on Tuesday. The strikes have garnered heavy criticism for being extrajudicial and carried out without Congressional authorization.

Keep reading

Congress Shouldn’t Bury a Hemp Ban in a Bill to Feed Families and Pay Our Troops

As Congress stumbles toward reopening the government, a quiet maneuver is unfolding, one that could devastate a thriving, new American industry.

Language added to the Agriculture-FDA Appropriations Bill would change the federal definition of hemp — the definition Congress passed in 2018 — in a way that would effectively outlaw nearly every hemp product on the market.

It’s being advanced through the appropriations process, so it’s not subject to the usual public hearings or debates.

A policy that could destroy hundreds of thousands of jobs and close thousands of farms and small businesses might pass in the same vote that funds food assistance programs and pays the military.

This proposal doesn’t just threaten my company. It threatens an entire ecosystem of farmers, manufacturers, distributors and retailers that grew under rules established by Congress. The 2018 Farm Bill legalized hemp products with less than 0.3% Delta-9 THC. Businesses like mine invested, hired and innovated within that framework.

Seven years later, hemp is a $28-billion-a-year industry that’s rapidly growing. It supports 320,000 American jobs and generates $1.5 billion in state tax revenue, according to Whitney Economics and USDA data. Major retailers such as Target, Circle K and Total Wine and More have embraced hemp-derived beverages because consumer demand is overwhelming.

This is no longer a niche market — it’s a national one, built by individuals and passionate visionaries. Hemp products ranging from CBD gummies to THC seltzers line shelves in stores across the country.

The proposed language would make those same products illegal overnight. It would wipe out all regulations at the state level, criminalize legitimate businesses, eliminate profitable hemp-farming acreage and force countless adult consumers to the black market, thanks to a heavy-handed federal decision.

Keep reading

Congressional Deal Would Ban Many Hemp THC Products, While Excluding Provisions To Let VA Doctors Recommend Medical Marijuana

Newly released spending legislation negotiated by congressional leaders would federally recriminalize many hemp-derived products. It also excludes provisions previously passed by the House and Senate that would have allowed Department of Veterans Affairs (VA) doctors to begin issuing medical marijuana recommendations to their patients.

The new measure, if enacted into law, would ban certain hemp products that were legalized under the 2018 Farm Bill signed into law by President Donald Trump during his first term.

The negotiated bill “prevents the unregulated sale of intoxicating hemp-based or hemp-derived products, including Delta-8, from being sold online, in gas stations, and corner stores, while preserving non-intoxicating CBD and industrial hemp products,” a summary published on Sunday by the Senate Appropriations Committee says.

Under current law, cannabis products are considered legal hemp if they contain less than 0.3 percent delta-9 THC on a dry weight basis.

The new legislation specifies that, within one year of enactment, the weight would apply to total THC—including delta-8 and other isomers. It would also include “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).”

The new definition of legal hemp would additionally ban “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or not capable of being naturally produced by it.

Legal hemp products would be limited to a total of .4 milligrams of total THC or any other cannabinoids with similar effects.

Within 90 days of the bill’s enactment, the Food and Drug Administration (FDA) and other agencies would need to publish list of “all cannabinoids known to FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature,” “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant” and “all other know cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids.”

The deal was agreed to by Senate Appropriations Committee Chair Susan Collins (R-ME) and Sen. Patty Murray (D-WA), the ranking minority member on the panel, as well as House Appropriations Committee Chair Tom Cole (R-OK). But Rep. Rosa DeLauro (D-CT), the top Democrat on the House panel, did not sign off.

The language slightly differs from provisions included in legislation that had previously advanced out of the House and Senate Appropriations panels, which would have banned products containing any “quantifiable” amount of THC, to be determined by the HHS secretary and secretary of agriculture.

Separately, the newly released appropriations legislation excludes language that had been passed by either chamber earlier this year to let VA doctors recommend medical cannabis to their military veteran patients in states where it is legal.

Keep reading

Federal Officials Revise Sentencing Guidelines For Drug Selling Convictions

New amendments to federal sentencing guidelines will put less of an emphasis on the quantity of drugs someone was charged with, and give more consideration to the scope of their role in the overall drug distribution chain. The United States Sentencing Commission implemented the amendments November 1.

Federal sentencing is calculated using a deeply convoluted scoring system that assigns a base offense level (BOL) between 1 and 43, according to how serious a conviction is perceived to be. For drug-trafficking, this is determined partly through a Drug Quantity Table that uses the number of grams involved to assign a BOL that—prior to the new amendments—could be between 6 and 38. But about two out of three people were being sentenced using a BOL of between 30 and 38.

The fixation with quantity as the biggest factor in how serious each case made it easy to prosecute local distributors as if they were high-level members of drug trafficking organizations. Neighborhood sellers who might only deal in relatively small quantities could still be assigned a BOL for much larger quantities, if the number was measured over a long period of time or manipulated in other ways.

The length of someone’s prison sentence also depends on other factors like prior convictions, but a higher BOL correlates to a longer sentence. For a BOL of 37 or higher, the upper end of the sentencing range can be life in prison, depending on the person’s criminal-legal history.

Now, BOL will be capped at 32 for people determined to have a “mitigating role” in the violation—meaning those at the lower end of the supply chain—and the USSC is supporting a broader application of that standard. A BOL of 32 means a sentencing range of roughly between 10 and 22 years.

“An adjustment…is generally warranted if the defendant’s primary function in the offense was plainly among the lowest level of drug trafficking functions, such as serving as a courier, running errands, sending or receiving phone calls or messages, or acting as a lookout,” state the guidelines. “[Or] if the defendant’s primary function in the offense was performing another low-level trafficking function, such as distributing controlled substances in user-level quantities for little or no monetary compensation or with a primary motivation other than profit.”

Primary motivations other than profit could include personal relationships, or being threatened or coerced. The USSC is still considering whether to apply the adjustment retroactively.

Keep reading

Tariffs, Tobacco, and Policy Whiplash

When politicians talk tough on trade, they usually promise to protect American jobs. But sometimes those gestures do the opposite. The Trump administration’s proposed 100 percent tariff on large cigars imported from Nicaragua is a case in point. According to my latest research, the tariff would shrink US GDP by $1.26 billion, reduce total output by $2.06 billion, eliminate nearly 18,000 jobs, and cost state and local governments $95 million in tax revenue.

There is no domestic industry to protect. The United States produces almost no large cigars, which are rolled by hand from long tobacco leaves and sold through tobacconists, cigar lounges, and small brick-and-mortar shops. Roughly 60 percent of all 430 million cigars imported each year come from Nicaragua. Doubling landed import costs would devastate the 3,500 retailers and 50,000 workers whose livelihoods depend on that trade.

Worse, this tariff reverses one of the administration’s genuine policy successes—its early effort to limit the Food and Drug Administration’s overreach into small-batch cigars and other low-risk nicotine products. It also repeats the same arbitrary logic behind the FDA’s recent warning letter to NOAT—a Swedish company selling mild, recyclable nicotine pouches already cleared for sale in Europe. In both cases, symbolic toughness trumps scientific and economic sense.

Keep reading

Trump’s Weight-loss Drug Deal: Cheaper Shots, But Is It MAHA?

President Donald Trump has unveiled a sweeping action to slash the cost of the nation’s most expensive weight-loss drugs, casting it as a turning point for both healthcare affordability and economic fairness. In what the White House calls a “historic” agreement with pharmaceutical giants Eli Lilly and Novo Nordisk, the administration announced that prices for popular GLP-1 agonists (weight-loss drugs) such as Ozempic and Wegovy will drop by more than two-thirds under a new initiative known as TrumpRx. The program is a government-backed platform that allows Americans to purchase prescription drugs at discounted rates negotiated by the administration.

The measure, described by officials as one of the largest single reductions in drug prices in U.S. history, aims to make medications long seen as luxury treatments accessible to millions of Americans battling obesity and related conditions.

Applause for the move was far from unanimous. Within the “Make America Healthy Again” (MAHA) camp — the wing of the movement that believes real health starts with prevention rather than prescriptions — the mood was restrained. Critics argue that the deal hands pharmaceutical companies both market dominance and political validation, locking Americans further into a medical model driven by patented injections.

The Deal

The White House framed the deal as a landmark victory for American consumers:

The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.

Under the terms of the new arrangement, the monthly cost of Ozempic and Wegovy will fall from about $1,000 and $1,350, respectively, to $350 when purchased through TrumpRx. Prices for Eli Lilly’s Zepbound and Orforglipron, once approved, will be reduced from $1,086 to an average of $346. If — or rather when — the FDA later authorizes the Wegovy pill or similar oral GLP-1 drugs currently in development, “the initial dose of those drugs will be priced at $150 per month” through the portal.

The administration said the new pricing will allow Medicare and Medicaid to cover obesity treatments “at a dramatically lower cost to taxpayers than that proposed by the Biden Administration.” Under the agreement, Medicare will pay just $245 a month for drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. That is less than half of prior proposals.

According to the fact sheet:

These low prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.

Beneficiaries “will pay a co-pay of just $50 per month.” Plus, “state Medicaid programs will also have access to these medications at these prices.”

The deal also extends to other high-cost medicines. Eli Lilly’s Emgality, a migraine therapy, will now cost $299 per pen, down $443 from its list price. Trulicity, another diabetes treatment, will fall to $389 per month, a reduction of nearly $600. Novo Nordisk’s insulin products NovoLog and Tresiba will be capped at $35 per monthly supply.

Keep reading

Psilocybin Shows Potential to Improve Long-Term Effects of Repetitive Brain Injuries Linked to Intimate Partner Violence

The research involved teams from the University of Victoria, Monash University, and Vancouver Island University.

The study examined a rat model designed to mimic the types of injuries commonly reported in IPV survivors: repeated mild traumatic brain injury and short episodes of non-fatal strangulation. Female rats received daily head impacts followed by 90-second strangulation events for five consecutive days, then were allowed a 16-week recovery period to mirror the chronic symptoms often seen in humans.

After the recovery period, the animals were given either a single dose of psilocybin (1 mg/kg) or saline. Those that received psilocybin showed notable improvements. Anxiety-like behaviors normalized in the elevated plus-maze, measures of motivation improved through increased sucrose preference, and cognitive performance strengthened in both spatial-memory and reversal-learning tests. These benefits disappeared when rats were pre-treated with a 5-HT2A receptor–blocking compound, indicating that psilocybin’s effects were driven by this serotonin receptor.

The brain analysis aligned with the behavioral results. Injured rats that received saline had more activated microglia—an indicator of neuroinflammation—in the dorsal hippocampus, as well as fewer reelin-positive cells linked to neuroplasticity. Those alterations were not present in the psilocybin-treated group.

Taken together, the findings suggest that psilocybin’s antidepressant-like, pro-cognitive, and anti-inflammatory actions may help counter long-term effects of repetitive IPV-related brain injury, and that the 5-HT2A receptor plays a key role in those benefits.

Keep reading

Hemp Shows Strong Antiviral Activity Against Japanese Encephalitis Virus

The research, published by Arch Virol and conducted by scientists from Chung-Ang University, The Catholic University of Korea, Kyungpook National University and Gyeongkuk National University, analyzed whether extracts from hemp roots and stems could limit viral activity in cell models.

The team prepared ethanol extracts and organic solvent fractions from hemp material, first identifying non-toxic concentration ranges through standard cytotoxicity assays. Several of these fractions showed strong virucidal effects, but the hexane and chloroform fractions stood out for producing the most pronounced suppression of viral activity.

When these highly active fractions were applied after cells had already been infected, researchers observed a sharp reduction in viral replication. Both JEV mRNA and the viral E protein dropped substantially, indicating that the post-treatment approach directly interfered with the virus’s ability to grow. By contrast, applying the fractions before viral exposure—or at the same time as exposure—did not offer meaningful protection, suggesting the compounds work most effectively once infection is underway.

Further chemical analysis identified several known hemp-derived molecules within the active fractions, and one compound in particular, stigmasterol, emerged as a key antiviral candidate. In follow-up tests, stigmasterol demonstrated both virucidal action and direct antiviral activity. It disrupted viral entry during infection and suppressed viral growth afterward, again reducing JEV mRNA and E protein expression to significant levels.

Keep reading